1. Home
  2. FTRE vs BHC Comparison

FTRE vs BHC Comparison

Compare FTRE & BHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Fortrea Holdings Inc.

FTRE

Fortrea Holdings Inc.

N/A

Current Price

$21.06

Market Cap

1.9B

Sector

Health Care

ML Signal

N/A

Logo Bausch Health Companies Inc.

BHC

Bausch Health Companies Inc.

N/A

Current Price

$8.21

Market Cap

2.3B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
FTRE
BHC
Founded
1996
N/A
Country
United States
Canada
Employees
N/A
N/A
Industry
Medical Specialities
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.9B
2.3B
IPO Year
2023
1996

Fundamental Metrics

Financial Performance
Metric
FTRE
BHC
Price
$21.06
$8.21
Analyst Decision
Buy
Hold
Analyst Count
13
7
Target Price
★ $22.63
$7.70
AVG Volume (30 Days)
1.9M
★ 3.0M
Earning Date
10-29-2026
10-28-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 423.08
EPS
★ N/A
N/A
Revenue
$2,723,400,000.00
★ $8,724,000,000.00
Revenue This Year
N/A
$6.81
Revenue Next Year
$3.11
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 1.00
N/A
52 Week Low
$8.55
$4.33
52 Week High
$26.16
$9.04

Technical Indicators

Market Signals
Indicator
FTRE
BHC
Relative Strength Index (RSI) 45.85 74.93
Support Level $16.34 $5.49
Resistance Level $21.25 N/A
Average True Range (ATR) 1.36 0.37
MACD -0.11 0.24
Stochastic Oscillator 15.57 78.69

Price Performance

Historical Comparison
FTRE
BHC

About FTRE Fortrea Holdings Inc.

Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion.

About BHC Bausch Health Companies Inc.

Bausch Health Companies Inc is a world-wide specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum of its revenue from the Bausch + Lomb segment.

Share on Social Networks: